Rep. Mike Fitzpatrick accused top leaders of Brigham & Women's Hospital of retaliating against patient advocates Amy Reed and Hooman Noorchashm when a hospital administrator declared the couple a security threat and subjected them to a physical search.
What does it say about our national commitment to research integrity that the Department of Health and Human Services' Office of Research Integrity has concluded that a five-year ban on federal research funding for one individual researcher is a sufficient response to a case involving millions of taxpayer dollars, completely fabricated data, and hundreds to thousands of patients in invasive clinical trials?
After a five-year investigation, the HHS Office of Research Integrity announced that it has settled with former Duke University researcher Anil Potti.
NCI named the inaugural 43 recipients of its Outstanding Investigator Awards.
NCI awarded eight new, competing and renewed grants as part of its funding for its Specialized Programs of Research Excellence. The grantees will receive $2,185,000 per year for five years.
THE DEATH OF CANCER After Fifty Years on the Front Lines of Medicine, a Pioneering Oncologist Reveals Why the War on Cancer Is Winnable–and How We Can Get There. By Vincent T. DeVita, Jr. and Elizabeth DeVita-Raeburn; Illustrated. 336 pp. Sarah Crichton Books, Farrar, Strauss & Giroux. $28.00“The Emperor of All Maladies” was a history of oncology, and a good one. “The Death of Cancer” is a memoir of one of the greats of medical oncology. It is a history from someone who was there, making history.
Vincent T. DeVita Jr. has seen the cancer field as a confident young doc eager to challenge the system, as a general in the War on Cancer, as an academic oncologist and, most recently, as a patient.
A Boston judge ruled Nov. 3 that Brigham & Women's Hospital had violated the First Amendment rights of a couple who led an aggressive national campaign to stop power morcellation, a surgical procedure routinely used by gynecologists.
Hospitals serving large populations of low-income patients stand to lose up to seven figures a year in drug discounts if proposed regulatory changes to the 340B program are enacted, the program's supporters say.
Congress passed a two-year budget deal that would raise government spending as well as the debt ceiling.
